Synonymer & Information om | Engelska ordet NAFLD

Exempel på hur man kan använda NAFLD i en mening

• The absence of fat tissue is associated with insulin resistance, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome.
• The main subtypes of fatty liver disease are metabolic dysfunction–associated steatotic liver disease (MASLD, formerly "non-alcoholic fatty liver disease" (NAFLD)) and alcohol-associated liver disease (ALD), with the category "metabolic and alcohol associated liver disease" (metALD) describing an overlap of the two.
• Nonalcoholic steatohepatitis (NASH) is a disease that has progressed from nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation and fibrosis.
• Abundant availability of nicotinamide leads to depletion of both nicotinamide adenine dinucleotide (NAD+) and SAM-e, resulting in liver steatosis and fibrosis, causing the progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH).
• Artificial Insulin Delivery System (AIDPIT); Diabetes and Cancer Study Group; Diabetes Education Study Group (DESG); Diabetic Pregnancy Study Group (DPSG); Non-alcoholic fatty liver disease (NAFLD); Diabetes Neuropathy Study Group (NEURODIAB); EASD Eye Complication Study Group (EASDEC); European Diabetic Nephropathy Study Group (EDNSG); Incretin Study Group; EASD Islet Study Group; European Diabetes Epidemiology Group (EDEG); Diabetes and Nutrition Study Group (DNSG); Psychosocial Aspects of Diabetes (PSAD); Diabetic Foot Study Group (DFSG); EASD Study Group on Primary Care Research in Diabetology (PCCD); Genetics of Diabetes Study Group; Diabetes and Cardiovascular Disease Study Group (D&CVD).
• Cirrhosis is most commonly caused by alcohol-related liver disease, metabolic dysfunction–associated steatohepatitis (MASH – the progressive form of metabolic dysfunction–associated steatotic liver disease, previously called non-alcoholic fatty liver disease or NAFLD), heroin abuse, chronic hepatitis B, and chronic hepatitis C.
• Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus, dyslipidemia, NASH and NAFLD It is approved for use in India by the Drug Controller General of India.
• He helped and led the GoI in 2021 into Integration of Non-Alcoholic Fatty Liver Disease (NAFLD) within the ambit of NCDs, making India the first country globally (covered by the Lancet, applauded by DG, WHO).
• Volixibat (INN; development code SHP626) is a medication under development as a possible treatment for nonalcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).
• 17β-HSD13 is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.
• This oxidation could be caused by tissue steatosis and hypoxia as a consequence of inflammation in fatty liver, NASH or NAFLD, in obese people or even, on a subclinical level, in the elderly.
• Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or semaglutide.
• Assy has contributed to the field of hepatology by researching cytokine expression in fatty liver diseases, revealing links between hepatic fatty liver disease, soft drinks, and coronary artery disease, while also focusing on viral hepatitis (B and C), nonalcoholic fatty liver disease (NAFLD) treatment, and leading studies on the impact of liver fat on coronary artery diseases.
• In a comparison study with BMI and five other metrics – a body shape index, conicity index, body adiposity index, waist–hip ratio, and abdominal volume index (AVI) – BRI and AVI proved most effective at predicting risk of developing nonalcoholic fatty liver disease (NAFLD).

Förberedelsen av sidan tog: 288,03 ms.